Insider transactions

EDGAR

SUPERNUS PHARMACEUTICALS, INC.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-21.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
20 transactions, 202,091 shares
Sum of shares × price per share: 10,264,930.31

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–50 of 323

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-11-02 Filed 2026-11-04NEWHALL CHARLES W III Director
J

Other acquisition or disposition (describe transaction)

Common Stock
Disposed (D)124,1190—0Direct (D) No
F1
  • F1 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/26, Artemis Merger Sub Inc. merged with and into Supernus Pharmaceuticals, with Supernus Pharmaceuticals surviving as a wholly-owned subsidiary of Indivior. At the effective time, each outstanding share of Supernus Pharmaceuticals common stock was cancelled and automatically converted into the right to receive 1.5401 shares of Indivior common stock. In connection with the merger, Indivior changed its name to Supernus, Inc. The reporting person's shares of Supernus Pharmaceuticals common stock were disposed of, and the shares of Supernus, Inc. common stock received in exchange were acquired, pursuant to the merger. The reporting person received no cash consideration other than cash in lieu of a fractional share.
Open filing 0001005544-26-000006 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-04NEWHALL CHARLES W III Director
J

Other acquisition or disposition (describe transaction)

Derivative security: Restricted Stock Unit — underlying Common Stock (2,989)
Disposed (D)2,9890—0Direct (D) No
F2, F3, F4
  • F2 Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
  • F3 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
  • F4 These restricted stock units will be settled in common stock upon vesting, which will occur on February 18, 2027.
Open filing 0001005544-26-000006 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-04NEWHALL CHARLES W III Director
J

Other acquisition or disposition (describe transaction)

Derivative security: Director Stock Option (Right to Buy) — underlying Common Stock (7,905) — exercise price 25.30
Disposed (D)7,9050—0Direct (D) No
F3
  • F3 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
Open filing 0001005544-26-000006 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-04NEWHALL CHARLES W III Director
J

Other acquisition or disposition (describe transaction)

Derivative security: Director Stock Option (Right to Buy) — underlying Common Stock (6,036) — exercise price 38.60
Disposed (D)6,0360—0Direct (D) No
F3
  • F3 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
Open filing 0001005544-26-000006 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-04NEWHALL CHARLES W III Director
J

Other acquisition or disposition (describe transaction)

Derivative security: Director Stock Option (Right to Buy) — underlying Common Stock (8,613) — exercise price 39.40
Disposed (D)8,6130—0Direct (D) No
F3
  • F3 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
Open filing 0001005544-26-000006 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-04NEWHALL CHARLES W III Director
J

Other acquisition or disposition (describe transaction)

Derivative security: Director Stock Option (Right to Buy) — underlying Common Stock (12,427) — exercise price 36.75
Disposed (D)12,4270—0Direct (D) No
F3
  • F3 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
Open filing 0001005544-26-000006 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-04NEWHALL CHARLES W III Director
J

Other acquisition or disposition (describe transaction)

Derivative security: Director Stock Option (Right to Buy) — underlying Common Stock (9,305) — exercise price 23.99
Disposed (D)9,3050—0Direct (D) No
F3
  • F3 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
Open filing 0001005544-26-000006 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-04NEWHALL CHARLES W III Director
J

Other acquisition or disposition (describe transaction)

Derivative security: Director Stock Option (Right to Buy) — underlying Common Stock (7,365) — exercise price 29.61
Disposed (D)7,3650—0Direct (D) No
F3
  • F3 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
Open filing 0001005544-26-000006 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-04NEWHALL CHARLES W III Director
J

Other acquisition or disposition (describe transaction)

Derivative security: Director Stock Option (Right to Buy) — underlying Common Stock (6,847) — exercise price 32.20
Disposed (D)6,8470—0Direct (D) No
F3
  • F3 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
Open filing 0001005544-26-000006 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-04NEWHALL CHARLES W III Director
J

Other acquisition or disposition (describe transaction)

Derivative security: Director Stock Option (Right to Buy) — underlying Common Stock (6,293) — exercise price 38.60
Disposed (D)6,2930—0Direct (D) No
F3, F5
  • F3 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
  • F5 The option vests on February 23, 2024.
Open filing 0001005544-26-000006 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-04NEWHALL CHARLES W III Director
J

Other acquisition or disposition (describe transaction)

Derivative security: Director Stock Option (Right to Buy) — underlying Common Stock (8,252) — exercise price 27.94
Disposed (D)8,2520—0Direct (D) No
F3, F6
  • F3 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
  • F6 The option vests on February 22, 2025.
Open filing 0001005544-26-000006 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-04NEWHALL CHARLES W III Director
J

Other acquisition or disposition (describe transaction)

Derivative security: Director Stock Option (Right to Buy) — underlying Common Stock (7,296) — exercise price 33.52
Disposed (D)7,2960—0Direct (D) No
F3, F7
  • F3 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
  • F7 The option vests on February 19, 2026.
Open filing 0001005544-26-000006 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-04NEWHALL CHARLES W III Director
J

Other acquisition or disposition (describe transaction)

Derivative security: Director Stock Option (Right to Buy) — underlying Common Stock (4,977) — exercise price 50.20
Disposed (D)4,9770—0Direct (D) No
F3, F8
  • F3 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
  • F8 Each option vests on February 18, 2027.
Open filing 0001005544-26-000006 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-04Sensenig Bethany Director
J

Other acquisition or disposition (describe transaction)

Derivative security: Director Stock Option (Right to Buy) — underlying Common Stock (24,153) — exercise price 30.22
Disposed (D)24,1530—0Direct (D) No
F1, F2
  • F1 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
  • F2 The option vests in four equal annual installments beginning on August 17, 2024.
Open filing 0001899935-26-000009 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-04Sensenig Bethany Director
J

Other acquisition or disposition (describe transaction)

Derivative security: Director Stock Option (Right to Buy) — underlying Common Stock (8,252) — exercise price 27.94
Disposed (D)8,2520—0Direct (D) No
F1, F3
  • F1 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
  • F3 The option vests on February 22, 2025.
Open filing 0001899935-26-000009 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-04Sensenig Bethany Director
J

Other acquisition or disposition (describe transaction)

Derivative security: Director Stock Option (Right to Buy) — underlying Common Stock (7,296) — exercise price 33.52
Disposed (D)7,2960—0Direct (D) No
F1, F4
  • F1 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
  • F4 The option vests on February 19, 2026.
Open filing 0001899935-26-000009 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-04Sensenig Bethany Director
J

Other acquisition or disposition (describe transaction)

Derivative security: Director Stock Option (Right to Buy) — underlying Common Stock (4,977) — exercise price 50.20
Disposed (D)4,9770—0Direct (D) No
F1, F5
  • F1 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
  • F5 Each option vests on February 18, 2027.
Open filing 0001899935-26-000009 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-04Sensenig Bethany Director
J

Other acquisition or disposition (describe transaction)

Derivative security: Restricted Stock Unit — underlying Common Stock (2,989)
Disposed (D)2,9890—0Direct (D) No
F6, F1, F7
  • F6 Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
  • F1 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
  • F7 These restricted stock units will be settled in common stock upon vesting, which will occur on February 18, 2027.
Open filing 0001899935-26-000009 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-04Horich William Todd Officer: SVP, Commercial Operations
J

Other acquisition or disposition (describe transaction)

Derivative security: Restricted Stock Unit — underlying Common Stock (100,000) — exercise price 0
Disposed (D)100,0000—0Direct (D) No
F1, F2
  • F1 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
  • F2 These restricted stock units (RSUs) are settled in common stock upon vesting, which occurs in five installments. 40% of the RSUs vest upon the closing of the merger-of-equals transaction between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. (the Closing). 15% of the RSUs vest upon the one-year anniversary of the Closing. 15% of the RSUs vest upon the two-year anniversary of the Closing. 15% of the RSUs vest upon the three-year anniversary of the Closing. 15% of the RSUs vest upon the four-year anniversary of the Closing.
Open filing 0002117599-26-000009 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-04Horich William Todd Officer: SVP, Commercial Operations
J

Other acquisition or disposition (describe transaction)

Derivative security: Performance Share Unit — underlying Common Stock (5,000)
Disposed (D)5,0000—0Direct (D) No
F3, F1, F4
  • F3 Each performance share unit represents the right to receive one share of Supernus common stock upon vesting.
  • F1 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
  • F4 On February 19, 2025, the Reporting Person was awarded Performance Share Units with individual performance objectives and a defined performance period established on May 3, 2025.
Open filing 0002117599-26-000009 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-04Horich William Todd Officer: SVP, Commercial Operations
J

Other acquisition or disposition (describe transaction)

Derivative security: Performance Share Unit — underlying Common Stock (3,500)
Disposed (D)3,5000—0Direct (D) No
F3, F1, F5
  • F3 Each performance share unit represents the right to receive one share of Supernus common stock upon vesting.
  • F1 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
  • F5 On February 18, 2026, the Reporting Person was awarded Performance Share Units with individual performance objectives and a defined performance period established on July 15, 2026.
Open filing 0002117599-26-000009 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-04Horich William Todd Officer: SVP, Commercial Operations
J

Other acquisition or disposition (describe transaction)

Derivative security: Restricted Stock Unit — underlying Common Stock (6,250)
Disposed (D)6,2500—0Direct (D) No
F6, F1, F7
  • F6 Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
  • F1 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
  • F7 These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024.
Open filing 0002117599-26-000009 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-04Horich William Todd Officer: SVP, Commercial Operations
J

Other acquisition or disposition (describe transaction)

Derivative security: Restricted Stock Unit — underlying Common Stock (2,500)
Disposed (D)2,5000—0Direct (D) No
F6, F1, F8
  • F6 Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
  • F1 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
  • F8 These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2025.
Open filing 0002117599-26-000009 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-04Horich William Todd Officer: SVP, Commercial Operations
J

Other acquisition or disposition (describe transaction)

Derivative security: Restricted Stock Unit — underlying Common Stock (3,375)
Disposed (D)3,3750—0Direct (D) No
F6, F1, F9
  • F6 Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
  • F1 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
  • F9 These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 19, 2026.
Open filing 0002117599-26-000009 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-04Horich William Todd Officer: SVP, Commercial Operations
J

Other acquisition or disposition (describe transaction)

Derivative security: Restricted Stock Unit — underlying Common Stock (3,000)
Disposed (D)3,0000—0Direct (D) No
F6, F1, F10
  • F6 Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
  • F1 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
  • F10 These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 18, 2027.
Open filing 0002117599-26-000009 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-04Horich William Todd Officer: SVP, Commercial Operations
J

Other acquisition or disposition (describe transaction)

Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock (13,000) — exercise price 39.40
Disposed (D)13,0000—0Direct (D) No
F1, F11
  • F1 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
  • F11 The option vests in four equal annual installments beginning on February 14, 2019.
Open filing 0002117599-26-000009 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-04Horich William Todd Officer: SVP, Commercial Operations
J

Other acquisition or disposition (describe transaction)

Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock (14,000) — exercise price 36.75
Disposed (D)14,0000—0Direct (D) No
F1, F12
  • F1 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
  • F12 The option vests in four equal annual installments beginning on February 22, 2020.
Open filing 0002117599-26-000009 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-04Horich William Todd Officer: SVP, Commercial Operations
J

Other acquisition or disposition (describe transaction)

Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock (17,000) — exercise price 29.61
Disposed (D)17,0000—0Direct (D) No
F1, F13
  • F1 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
  • F13 The option vests in four equal annual installments beginning on February 19, 2022.
Open filing 0002117599-26-000009 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-04Horich William Todd Officer: SVP, Commercial Operations
J

Other acquisition or disposition (describe transaction)

Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock (18,000) — exercise price 32.20
Disposed (D)18,0000—0Direct (D) No
F1, F14
  • F1 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
  • F14 The option vests in four equal annual installments beginning on February 22, 2023.
Open filing 0002117599-26-000009 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-04Horich William Todd Officer: SVP, Commercial Operations
J

Other acquisition or disposition (describe transaction)

Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock (20,000) — exercise price 38.60
Disposed (D)20,0000—0Direct (D) No
F1, F15
  • F1 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
  • F15 The option vests in four equal annual installments beginning on February 23, 2024.
Open filing 0002117599-26-000009 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-04Horich William Todd Officer: SVP, Commercial Operations
J

Other acquisition or disposition (describe transaction)

Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock (25,000) — exercise price 27.94
Disposed (D)25,0000—0Direct (D) No
F1, F16
  • F1 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
  • F16 The option vests in four equal annual installments beginning on February 22, 2025.
Open filing 0002117599-26-000009 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-04Horich William Todd Officer: SVP, Commercial Operations
J

Other acquisition or disposition (describe transaction)

Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock (20,000) — exercise price 33.52
Disposed (D)20,0000—0Direct (D) No
F1, F17
  • F1 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
  • F17 The option vests in four equal annual installments beginning on February 19, 2026.
Open filing 0002117599-26-000009 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-04Horich William Todd Officer: SVP, Commercial Operations
J

Other acquisition or disposition (describe transaction)

Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock (13,500) — exercise price 50.20
Disposed (D)13,5000—0Direct (D) No
F1, F18
  • F1 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
  • F18 The option vests in four equal annual installments beginning on February 18, 2027.
Open filing 0002117599-26-000009 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-04Bhatt Padmanabh P. Officer: Sr. VP of IP, CSO
J

Other acquisition or disposition (describe transaction)

Common Stock
Disposed (D)18,6370—0Direct (D) No
F1
  • F1 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/26, Artemis Merger Sub Inc. merged with and into Supernus Pharmaceuticals, with Supernus Pharmaceuticals surviving as a wholly-owned subsidiary of Indivior. At the effective time, each outstanding share of Supernus Pharmaceuticals common stock was cancelled and automatically converted into the right to receive 1.5401 shares of Indivior common stock. In connection with the merger, Indivior changed its name to Supernus, Inc. The reporting person's shares of Supernus Pharmaceuticals common stock were disposed of, and the shares of Supernus, Inc. common stock received in exchange were acquired, pursuant to the merger. The reporting person received no cash consideration other than cash in lieu of a fractional share.
Open filing 0001539215-26-000014 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-04Bhatt Padmanabh P. Officer: Sr. VP of IP, CSO
J

Other acquisition or disposition (describe transaction)

Derivative security: Performance Share Unit — underlying Common Stock (3,350)
Disposed (D)3,3500—0Direct (D) No
F2, F3, F4
  • F2 Each performance share unit represents the right to receive one share of Supernus common stock upon vesting.
  • F3 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
  • F4 On February 22, 2024, the Reporting Person was awarded Performance Share Units with individual performance objectives and a defined performance period established on June 24, 2024.
Open filing 0001539215-26-000014 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-04Bhatt Padmanabh P. Officer: Sr. VP of IP, CSO
J

Other acquisition or disposition (describe transaction)

Derivative security: Performance Share Unit — underlying Common Stock (2,500)
Disposed (D)2,5000—0Direct (D) No
F2, F3, F5
  • F2 Each performance share unit represents the right to receive one share of Supernus common stock upon vesting.
  • F3 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
  • F5 On February 19, 2025, the Reporting Person was awarded Performance Share Units with individual performance objectives and a defined performance period established on May 3, 2025.
Open filing 0001539215-26-000014 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-04Bhatt Padmanabh P. Officer: Sr. VP of IP, CSO
J

Other acquisition or disposition (describe transaction)

Derivative security: Performance Share Unit — underlying Common Stock (3,500)
Disposed (D)3,5000—0Direct (D) No
F2, F3, F6
  • F2 Each performance share unit represents the right to receive one share of Supernus common stock upon vesting.
  • F3 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
  • F6 On February 18, 2026, the Reporting Person was awarded Performance Share Units with individual performance objectives and a defined performance period established on July 15, 2026.
Open filing 0001539215-26-000014 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-04Bhatt Padmanabh P. Officer: Sr. VP of IP, CSO
J

Other acquisition or disposition (describe transaction)

Derivative security: Restricted Stock Unit — underlying Common Stock (100,000) — exercise price 0
Disposed (D)100,0000—0Direct (D) No
F3, F7
  • F3 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
  • F7 These restricted stock units (RSUs) are settled in common stock upon vesting, which occurs in four installments. 50% of the RSUs vest upon the closing of the merger-of-equals transaction between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. (the Closing). 15% of the RSUs vest upon the one-year anniversary of the Closing. 15% of the RSUs vest upon the two-year anniversary of the Closing. 20% of the RSUs vest upon the three-year anniversary of the Closing.
Open filing 0001539215-26-000014 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-04Bhatt Padmanabh P. Officer: Sr. VP of IP, CSO
J

Other acquisition or disposition (describe transaction)

Derivative security: Restricted Stock Unit — underlying Common Stock (1,250)
Disposed (D)1,2500—0Direct (D) No
F8, F3, F9
  • F8 Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
  • F3 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
  • F9 These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024.
Open filing 0001539215-26-000014 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-04Bhatt Padmanabh P. Officer: Sr. VP of IP, CSO
J

Other acquisition or disposition (describe transaction)

Derivative security: Restricted Stock Unit — underlying Common Stock (2,500)
Disposed (D)2,5000—0Direct (D) No
F8, F3, F10
  • F8 Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
  • F3 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
  • F10 These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2025.
Open filing 0001539215-26-000014 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-04Bhatt Padmanabh P. Officer: Sr. VP of IP, CSO
J

Other acquisition or disposition (describe transaction)

Derivative security: Restricted Stock Unit — underlying Common Stock (3,375)
Disposed (D)3,3750—0Direct (D) No
F8, F3, F11
  • F8 Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
  • F3 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
  • F11 These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 19, 2026.
Open filing 0001539215-26-000014 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-04Bhatt Padmanabh P. Officer: Sr. VP of IP, CSO
J

Other acquisition or disposition (describe transaction)

Derivative security: Restricted Stock Unit — underlying Common Stock (3,000)
Disposed (D)3,0000—0Direct (D) No
F8, F3, F12
  • F8 Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
  • F3 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
  • F12 These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 18, 2027.
Open filing 0001539215-26-000014 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-04Bhatt Padmanabh P. Officer: Sr. VP of IP, CSO
J

Other acquisition or disposition (describe transaction)

Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock (5,000) — exercise price 38.60
Disposed (D)5,0000—0Direct (D) No
F3, F13
  • F3 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
  • F13 The option vests in four equal annual installments beginning on February 23, 2024.
Open filing 0001539215-26-000014 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-04Bhatt Padmanabh P. Officer: Sr. VP of IP, CSO
J

Other acquisition or disposition (describe transaction)

Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock (15,000) — exercise price 27.94
Disposed (D)15,0000—0Direct (D) No
F3, F14
  • F3 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
  • F14 The option vests in four equal annual installments beginning on February 22, 2025.
Open filing 0001539215-26-000014 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-04Bhatt Padmanabh P. Officer: Sr. VP of IP, CSO
J

Other acquisition or disposition (describe transaction)

Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock (20,000) — exercise price 33.52
Disposed (D)20,0000—0Direct (D) No
F3, F15
  • F3 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
  • F15 The option vests in four equal annual installments beginning on February 19, 2026.
Open filing 0001539215-26-000014 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-04Bhatt Padmanabh P. Officer: Sr. VP of IP, CSO
J

Other acquisition or disposition (describe transaction)

Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock (13,500) — exercise price 50.20
Disposed (D)13,5000—0Direct (D) No
F3, F16
  • F3 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
  • F16 The option vests in four equal annual installments beginning on February 18, 2027.
Open filing 0001539215-26-000014 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-04Khattar Jack A. Director · Officer: President, CEO
J

Other acquisition or disposition (describe transaction)

Common Stock
Disposed (D)1,258,3510—0Direct (D) No
F1
  • F1 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/26, Artemis Merger Sub Inc. merged with and into Supernus Pharmaceuticals, with Supernus Pharmaceuticals surviving as a wholly-owned subsidiary of Indivior. At the effective time, each outstanding share of Supernus Pharmaceuticals common stock was cancelled and automatically converted into the right to receive 1.5401 shares of Indivior common stock. In connection with the merger, Indivior changed its name to Supernus, Inc. The reporting person's shares of Supernus Pharmaceuticals common stock were disposed of, and the shares of Supernus, Inc. common stock received in exchange were acquired, pursuant to the merger. The reporting person received no cash consideration other than cash in lieu of a fractional share.
Open filing 0001539937-26-000016 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-04Khattar Jack A. Director · Officer: President, CEO
J

Other acquisition or disposition (describe transaction)

Common Stock
Disposed (D)958,1000—0Indirect (I) By the KBT TrustNo
F1
  • F1 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/26, Artemis Merger Sub Inc. merged with and into Supernus Pharmaceuticals, with Supernus Pharmaceuticals surviving as a wholly-owned subsidiary of Indivior. At the effective time, each outstanding share of Supernus Pharmaceuticals common stock was cancelled and automatically converted into the right to receive 1.5401 shares of Indivior common stock. In connection with the merger, Indivior changed its name to Supernus, Inc. The reporting person's shares of Supernus Pharmaceuticals common stock were disposed of, and the shares of Supernus, Inc. common stock received in exchange were acquired, pursuant to the merger. The reporting person received no cash consideration other than cash in lieu of a fractional share.
Open filing 0001539937-26-000016 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-04Khattar Jack A. Director · Officer: President, CEO
J

Other acquisition or disposition (describe transaction)

Derivative security: Restricted Stock Unit — underlying Common Stock (400,000) — exercise price 0
Disposed (D)400,0000—0Direct (D) No
F2, F3
  • F2 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
  • F3 These restricted stock units (RSUs) are settled in common stock upon vesting, which occurs in four installments. 50% of the RSUs vest upon the closing of the merger-of-equals transaction between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. (the Closing). 15% of the RSUs vest upon the one-year anniversary of the Closing. 15% of the RSUs vest upon the two-year anniversary of the Closing. 20% of the RSUs vest upon the three-year anniversary of the Closing.
Open filing 0001539937-26-000016 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-04Khattar Jack A. Director · Officer: President, CEO
J

Other acquisition or disposition (describe transaction)

Derivative security: Performance Share Unit — underlying Common Stock (19,320)
Disposed (D)19,3200—0Direct (D) No
F4, F2, F5
  • F4 Each performance share unit represents the right to receive one share of Supernus common stock upon vesting.
  • F2 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
  • F5 On February 22, 2024, the Reporting Person was awarded Performance Share Units with individual performance objectives and a defined performance period established on June 24, 2024.
Open filing 0001539937-26-000016 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

No Form 13F position in this issuer is placed in the store. A holder not yet linked or not yet filed is absent, not zero.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

Showing 1–9 of 9

House members’ trades in this company, newest report first, as filed
MemberTransaction dateTypeAmountOwnerReport
Hon. Gilbert Cisneros (CA31)2026-03-03Purchase$1,001 - $15,0002026-04-07
Hon. Gilbert Cisneros (CA31)2025-12-11Purchase$1,001 - $15,0002026-01-12
Hon. Gilbert Cisneros (CA31)2025-10-09Sale (partial)$1,001 - $15,0002025-11-18
Hon. Gilbert Cisneros (CA31)2025-03-24Purchase$1,001 - $15,0002025-04-07
Hon. Josh Gottheimer (NJ05)2022-12-23Sale (partial)$1,001 - $15,000JT2023-01-13
Hon. Gilbert Cisneros (CA39)2020-11-13Purchase$1,001 - $15,0002020-12-15
Hon. Gilbert Cisneros (CA39)2020-07-17Purchase$1,001 - $15,0002020-08-19
Hon. Gilbert Cisneros (CA39)2020-06-01Purchase$1,001 - $15,0002020-06-16
Hon. Josh Gottheimer (NJ05)2020-05-28Purchase$1,001 - $15,000JT2020-06-10

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Integrated Core Strategies (US) LLC Common Stock, par value $0.001 per share6.23,605,227.0006/30/2026 Filed 2026-08-06SCHEDULE 13G/AAmendment 2Open filing 0001104659-26-092198 Dispute this row
Millennium Management LLC Common Stock, par value $0.001 per share6.63,853,212.0006/30/2026 Filed 2026-08-06SCHEDULE 13G/AAmendment 2Open filing 0001104659-26-092198 Dispute this row
Millennium Group Management LLC Common Stock, par value $0.001 per share6.63,853,212.0006/30/2026 Filed 2026-08-06SCHEDULE 13G/AAmendment 2Open filing 0001104659-26-092198 Dispute this row
Israel A. Englander Common Stock, par value $0.001 per share6.63,853,212.0006/30/2026 Filed 2026-08-06SCHEDULE 13G/AAmendment 2Open filing 0001104659-26-092198 Dispute this row
Vanguard Capital Management Common Stock5.032,900,88403/31/2026 Filed 2026-04-30SCHEDULE 13GOpen filing 0002100119-26-001141 Dispute this row
Vanguard Portfolio Management Common Stock5.663,263,30903/31/2026 Filed 2026-04-29SCHEDULE 13GOpen filing 0002100121-26-000723 Dispute this row
The Vanguard Group Common Stock0003/13/2026 Filed 2026-03-27SCHEDULE 13G/AAmendment 7Open filing 0000102909-26-002362 Dispute this row
Integrated Core Strategies (US) LLC Common Stock, par value $0.001 per share4.92,817,883.0002/11/2026 Filed 2026-02-18SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-017103 Dispute this row
Millennium Management LLC Common Stock, par value $0.001 per share5.73,281,615.0002/11/2026 Filed 2026-02-18SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-017103 Dispute this row
Millennium Group Management LLC Common Stock, par value $0.001 per share5.73,281,615.0002/11/2026 Filed 2026-02-18SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-017103 Dispute this row
Israel A. Englander Common Stock, par value $0.001 per share5.73,281,615.0002/11/2026 Filed 2026-02-18SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-017103 Dispute this row
Millennium Management LLC Common Stock, par value $0.001 per share5.33,036,123.0001/26/2026 Filed 2026-02-02SCHEDULE 13GOpen filing 0001104659-26-009251 Dispute this row
Millennium Group Management LLC Common Stock, par value $0.001 per share5.33,036,123.0001/26/2026 Filed 2026-02-02SCHEDULE 13GOpen filing 0001104659-26-009251 Dispute this row
Israel A. Englander Common Stock, par value $0.001 per share5.33,036,123.0001/26/2026 Filed 2026-02-02SCHEDULE 13GOpen filing 0001104659-26-009251 Dispute this row
Armistice Capital, LLC Common Stock, $0.001 par value per share4.822,764,000.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 10Open filing 0001172661-26-001226 Dispute this row
Steven Boyd Common Stock, $0.001 par value per share4.822,764,000.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 10Open filing 0001172661-26-001226 Dispute this row
Dimensional Fund Advisors LP Common Stock4.72,712,341.0012/31/2025 Filed 2026-01-21SCHEDULE 13G/AAmendment 1Open filing 0000354204-26-000340 Dispute this row
Armistice Capital, LLC Common Stock, $0.001 par value per share5.062,836,000.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 9Open filing 0001172661-25-005158 Dispute this row
Steven Boyd Common Stock, $0.001 par value per share5.062,836,000.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 9Open filing 0001172661-25-005158 Dispute this row
Armistice Capital, LLC Common Stock, $0.001 par value per share8.584,812,000.0006/30/2025 Filed 2025-08-15SCHEDULE 13G/AAmendment 8Open filing 0001172661-25-003632 Dispute this row
Steven Boyd Common Stock, $0.001 par value per share8.584,812,000.0006/30/2025 Filed 2025-08-15SCHEDULE 13G/AAmendment 8Open filing 0001172661-25-003632 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,665,594 filings read, dated 2004-06-14 to 2026-11-19: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
201582,681
2016222,642
2017222,009
2018223,345
2019216,482
2020226,343
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026263,123

Filings made before the SEC required XML are listed, not extracted.

Back to SUPERNUS PHARMACEUTICALS, INC.